Paper Details

  1. Home
  2. Paper Details

Strategies in the management of alemtuzumab-related side effects.

Author: KarlssonClaes, KimbyEva, LundinJeanette, MellstedtHåkan, OsterborgAnders

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This article discusses the side effect profile of alemtuzumab, a CD52 monoclonal antibody used to treat chemotherapy-refractory B-cell chronic lymphocytic leukemia. While alemtuzumab can cause transient infusion-related side effects, the major side effect is T-cell depletion, leading to an increased risk of infection, particularly cytomegalovirus reactivation.
Paper Details　
Original Abstract of the Article :
B-cell chronic lymphocytic leukemia has traditionally been treated with alkylating agents and purine analogues. The introduction of alemtuzumab, a CD52 monoclonal antibody with significant clinical activity in chemotherapy refractory B-cell chronic lymphocytic leukemia, is accompanied by a side effe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1053/j.seminoncol.2006.01.027

データ提供：米国国立医学図書館（NLM）

Managing the Side Effects of Alemtuzumab Therapy

Alemtuzumab is a monoclonal antibody that has proven effective in treating B-cell chronic lymphocytic leukemia, a type of blood cancer. However, like many medications, alemtuzumab can cause side effects. This research focuses on the management of alemtuzumab-related side effects, providing guidance for clinicians treating patients with this medication. The study discusses various side effects, including infusion-related reactions, neutropenia, and infections, and explores strategies for minimizing and managing these complications.

Minimizing and Managing Alemtuzumab-Related Side Effects

The study highlights the importance of proactive measures to minimize and manage alemtuzumab-related side effects. The use of corticosteroid prophylaxis, subcutaneous administration, and close monitoring for signs of infection can significantly reduce the risk of complications and improve treatment outcomes for patients receiving alemtuzumab therapy. The research provides practical recommendations for clinicians to ensure optimal patient care and minimize potential adverse events.

Balancing the Benefits and Risks of Alemtuzumab Therapy

This research underscores the need for a careful balance between the benefits and risks of alemtuzumab therapy. While alemtuzumab offers significant clinical activity in treating B-cell chronic lymphocytic leukemia, it is essential to be aware of the potential side effects and take appropriate measures to manage them. This study serves as a valuable guide for clinicians, helping them make informed decisions about treatment and optimize patient outcomes.

Dr. Camel's Conclusion

This study provides valuable insights into the management of alemtuzumab-related side effects, emphasizing the importance of careful monitoring and proactive measures to minimize potential complications. It is like navigating a treacherous desert landscape, where vigilance and preparation are essential for safe passage. The research reminds us that even with promising new treatments, it is crucial to be aware of the potential risks and take steps to mitigate them. The goal of medical treatment is to achieve optimal patient outcomes, and this study serves as a valuable guide in the journey towards achieving this goal.

Date :
  1. Date Completed 2006-06-30
  2. Date Revised 2021-12-03
Further Info :

Pubmed ID

16720201

DOI: Digital Object Identifier

10.1053/j.seminoncol.2006.01.027

Related Literature

Article Analysis
・Side Effects of valacyclovir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.